Search research articles
Contact Us
Filters
Showing results (41-50 of 84) with videos related to
Page
of 9
Sort By:
The Lancet. Oncology
|
February 6, 2008
CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial
Viviane Hess, Bengt Glimelius, Philipp Grawe, et al.
Journal of Gastrointestinal Oncology
|
August 27, 2016
Nab-paclitaxel as alternative treatment regimen in advanced cholangiocellular carcinoma
Matthias Unseld, Werner Scheithauer, Roman Weigl, et al.
Acta Oncologica (Stockholm, Sweden)
|
April 25, 2007
Phase II trial of pegylated liposomal doxorubicin (Caelyx) plus Gemcitabine in chemotherapeutically pretreated patients with advanced breast cancer
Herbert Ulrich-Pur, Gabriela V Kornek, Karin Haider, et al.
Journal of Cancer Research and Clinical Oncology
|
May 13, 2014
Maintenance treatment with the immunomodulator MGN1703, a Toll-like receptor 9 (TLR9) agonist, in patients with metastatic colorectal carcinoma and disease control after chemotherapy: a randomised, double-blind, placebo-controlled trial
Hans-Joachim Schmoll, Burghardt Wittig, Dirk Arnold, et al.
Therapeutic Advances in Medical Oncology
|
September 14, 2020
Microvascular density assessed by CD31 predicts clinical benefit upon bevacizumab treatment in metastatic colorectal cancer: results of the PassionATE study, a translational prospective Phase II study of capecitabine and irinotecan plus bevacizumab followed by capecitabine and oxaliplatin plus bevacizumab or the reverse sequence in patients in mCRC
Daniela Bianconi, Merima Herac, Florian Posch, et al.
Journal of Gastrointestinal Oncology
|
June 11, 2016
Dose modification and efficacy of nab-paclitaxel plus gemcitabine vs. gemcitabine for patients with metastatic pancreatic cancer: phase III MPACT trial
Werner Scheithauer, Ramesh K Ramanathan, Malcolm Moore, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 5, 2002
Randomized multicenter phase II trial of oxaliplatin plus irinotecan versus raltitrexed as first-line treatment in advanced colorectal cancer
Werner Scheithauer, Gabriela V Kornek, Markus Raderer, et al.
Thrombosis Research
|
October 7, 2015
Integrin beta-3 genetic variants and risk of venous thromboembolism in colorectal cancer patients
Daniela Bianconi, Alexandra Schuler, Clemens Pausz, et al.
Scientific Reports
|
July 9, 2017
Biochemical and genetic predictors of overall survival in patients with metastatic pancreatic cancer treated with capecitabine and nab-paclitaxel
Daniela Bianconi, Gerwin Heller, Daniel Spies, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 25, 2009
Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer
Eric Van Cutsem, Walter L Vervenne, Jaafar Bennouna, et al.
Page
of 9
Search research articles
Search
Showing results (41-50 of 84) with videos related to
Sort By:
Page
of 9
The Lancet. Oncology
|
February 6, 2008
CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial
Viviane Hess, Bengt Glimelius, Philipp Grawe, et al.
Journal of Gastrointestinal Oncology
|
August 27, 2016
Nab-paclitaxel as alternative treatment regimen in advanced cholangiocellular carcinoma
Matthias Unseld, Werner Scheithauer, Roman Weigl, et al.
Acta Oncologica (Stockholm, Sweden)
|
April 25, 2007
Phase II trial of pegylated liposomal doxorubicin (Caelyx) plus Gemcitabine in chemotherapeutically pretreated patients with advanced breast cancer
Herbert Ulrich-Pur, Gabriela V Kornek, Karin Haider, et al.
Journal of Cancer Research and Clinical Oncology
|
May 13, 2014
Maintenance treatment with the immunomodulator MGN1703, a Toll-like receptor 9 (TLR9) agonist, in patients with metastatic colorectal carcinoma and disease control after chemotherapy: a randomised, double-blind, placebo-controlled trial
Hans-Joachim Schmoll, Burghardt Wittig, Dirk Arnold, et al.
Therapeutic Advances in Medical Oncology
|
September 14, 2020
Microvascular density assessed by CD31 predicts clinical benefit upon bevacizumab treatment in metastatic colorectal cancer: results of the PassionATE study, a translational prospective Phase II study of capecitabine and irinotecan plus bevacizumab followed by capecitabine and oxaliplatin plus bevacizumab or the reverse sequence in patients in mCRC
Daniela Bianconi, Merima Herac, Florian Posch, et al.
Journal of Gastrointestinal Oncology
|
June 11, 2016
Dose modification and efficacy of nab-paclitaxel plus gemcitabine vs. gemcitabine for patients with metastatic pancreatic cancer: phase III MPACT trial
Werner Scheithauer, Ramesh K Ramanathan, Malcolm Moore, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 5, 2002
Randomized multicenter phase II trial of oxaliplatin plus irinotecan versus raltitrexed as first-line treatment in advanced colorectal cancer
Werner Scheithauer, Gabriela V Kornek, Markus Raderer, et al.
Thrombosis Research
|
October 7, 2015
Integrin beta-3 genetic variants and risk of venous thromboembolism in colorectal cancer patients
Daniela Bianconi, Alexandra Schuler, Clemens Pausz, et al.
Scientific Reports
|
July 9, 2017
Biochemical and genetic predictors of overall survival in patients with metastatic pancreatic cancer treated with capecitabine and nab-paclitaxel
Daniela Bianconi, Gerwin Heller, Daniel Spies, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 25, 2009
Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer
Eric Van Cutsem, Walter L Vervenne, Jaafar Bennouna, et al.
Page
of 9